Western blot shows lysates of mouse spleen non-B cells. PVDF Membrane was probed with 0.1 µg/mL of Sheep Anti-Mouse LRRC32/GARP Antigen Affinity-purified Polyclonal Antibody (Catalog # AF6229) followed by ...read more
LRRC32/GARP was detected in immersion fixed bEnd.3 mouse endothelioma cell line using Sheep Anti-Mouse LRRC32/GARP Antigen Affinity-purified Polyclonal Antibody (Catalog # AF6229) at 10 µg/mL for 3 hours at room ...read more
Chinese hamster ovary cell line CHO-derived recombinant mouse LRRC32/GARP Ile18-Asn628 Accession # NP_001106850
Detects mouse LRRC32/GARP in direct ELISAs. In direct ELISAs, approximately 20% cross-reactivity with recombinant human (rh) LRRC32 is observed and less than 5% cross-reactivity with rhLRRC3, rhLRRC4, and rhLRRC4B is observed.
Immunogen affinity purified
Test in a species/application not listed above to receive a full credit towards a future purchase.
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.
Immunogen affinity purified
Sterile PBS to a final concentration of 0.2 mg/mL.
This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.
Alternate Names for LRRC32/GARP Antibody
D11S833Eleucine-rich repeat-containing protein 32
Glycoprotein A repetitions predominantgarpin
leucine rich repeat containing 32
Leucine-rich repeat protein 32 (LRRC32), also known as GARP (glycoprotein A repetitions predominant), is an 80 kDa type I transmembrane glycoprotein (1). Mature mouse LRRC32 consists of a 608 amino acid (aa) extracellular domain (ECD) that contains 22 leucine-rich repeats, a 21 aa transmembrane segment, and a 14 aa cytoplasmic domain (2-4). Within the ECD, mouse LRRC32 shares 80 and 94% aa sequence identity with human and rat LRRC32, respectively. LRRC32 is widely expressed during embryogenesis and on adult platelets (4, 5). Among T cells, it is selectively expressed on activated FOXP3+ regulatory T cells (Treg) (6-10). LRRC32 expression promotes the acquisition of a Treg phenotype including reduced cellular proliferation, reduced cytokine secretion, and the capacity to suppress the proliferation of naïve T cells (6-8). LRRC32 binds directly to the TGF-beta latency associated peptide (LAP) and tethers latent TGF-beta on the surface of activated Treg cells (9, 10). The presentation of TGF-beta on Tregs contributes to their ability to suppress naïve T cell proliferation (11).
Battaglia, M. and M.G. Roncarolo (2009) Eur. J. Immunol. 39:3296.
Ollendorff, V. et al. (1994) Cell Growth Differ. 5:213.
Bella, J. et al. (2008) Cell Mol Life Sci. 65:2307.
Roubin, R. et al. (1996) Int. J. Dev. Biol. 40:545.
Macaulay, I.C. et al. (2007) Blood 109:3260.
Wang, R. et al. (2008) PloS ONE 3:e2705.
Wang, R. et al. (2009) Proc. Natl. Acad. Sci. 106:13439.
Probst-Kepper, M. et al. (2009) J. Cell. Mol. Med. 13:3343.
Tran, D.Q. et al. (2009) Proc. Natl. Acad. Sci. 106:13445.
Stockis, J. et al. (2009) Eur. J. Immunol. 39:3315.
Vignali, D.A. et al. (2008) Nat. Rev. Immunol. 8:523.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
Review this Product
Be the first to review our LRRC32/GARP Antibody and receive a gift card or discount.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.